Clinical Trial Update: Endostar First-line Treatment of Advanced NSCLC [Phase 2]

View source ↗

Summary

Update on a Phase 2 trial of Endostar as first-line treatment for advanced non-small cell lung cancer; the current trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Endostar (recombinant human endostatin)

Snippet

Sponsor: China Medical University, China | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN